Stratvocate offers a wealth of information and easy-to-use tools for those involved in federal contracting.

Subject: synthesis of prodrug analogs and cyclopentane peptide nucleic acid (PNA) precursors
Solicitation Number: 75N98026Q00819CREAGENINC
Notice Type: PRESOL
NAICS: 325414
Set-Aside: No Set aside used
Notice Published: 07-16-26
Response Due: 07-05-26

Agency: Department of Health and Human Services
Office: NATIONAL INSTITUTES OF HEALTH
Contact: Vishnuvajjala Hanumanth Rao This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Address: BETHESDA, MD 20892
Place of Performance: Bethesda, MD 20892


Click for official SAM (FBO) notice, additional information, and accompanying attachments

Background Information: The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health.? ? Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection. Ongoing studies have?identified?several promising?sulfanylbenzamide-derived compounds and?cyclopentane peptide?nucleic acid precursor materials with potential?applications?as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies.? ? To support these research efforts, the Synthetic Bioactive Molecules Section?requires?synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials. These materials are not commercially available and require specialized synthetic?expertise?and production capabilities to generate quantities sufficient for continued preclinical evaluation.? The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity,?optimize?lead candidates, and support advancement toward future clinical development.?